Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes

REFERENCES

• Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613–620
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, National Heart, Lung, and Blood Institute. Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood diseases, Available at: www.nhlbi.nih.gov/resources/docs/cht-book.htm Accessed June 19, 2008
   Google Scholar
• Celli B R, Mac Nee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2006, Available from: http://www.goldcopd.org
   Google Scholar
• Donaldson G C, Seemungal T A, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852
   PubMed Web of Science ®Google Scholar
• Seemungal T A, Donaldson G C, Paul E A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422
   PubMed Web of Science ®Google Scholar
• McGhan R, Radcliff T, Fish R, et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748–1755
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña J J, Martínez-García M A, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11)925–931
   PubMed Web of Science ®Google Scholar
• Niewoehner D E, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20–28
   PubMed Web of Science ®Google Scholar
• American Lung Association. Trends in chronic bronchitis and emphysema: morbidity and mortality. December, 2007, www.lungusa.org. Accessed June 20, 2008
   Google Scholar
• American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2, www.thoracic.org/go/copd Accessed June 20, 2008
   Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive disease. Am J Respir Crit Care Med 2007; 175: 144–149
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Ferguson G T, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Resp Med 2008; 102(8)1099–1108
   PubMed Web of Science ®Google Scholar
• Hanania N A, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the DISKUS inhaler for the treatment of COPD. Chest 2003; 124: 834–843
   PubMed Web of Science ®Google Scholar
• Donohue J F, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004; 3: 173–181
   PubMedGoogle Scholar
• Make B, Hanania N A, ZuWallack R, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005; 27: 531–542
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647–656
   PubMed Web of Science ®Google Scholar
• Jones P W, Quirk F H, Baveystock C M, et al. A self-complete measure for chronic airflow limitation, the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327
   PubMed Web of Science ®Google Scholar
• Mahler D A, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084–1091
   PubMed Web of Science ®Google Scholar
• Celli B R, Thomas N E, Anderson J A, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease results from the TORCH Study. Am J Respir Crit Care Med 2008; 178: 332–338
   PubMed Web of Science ®Google Scholar
• Van Der Valk P, Monninkhof E, Van Der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358–1363
   PubMed Web of Science ®Google Scholar
• Wouters E F, Postma D S, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480–448
   PubMed Web of Science ®Google Scholar
• Woodhead M. Inhaled corticosteroids cause pneumonia … or do they?. Am J Respir Crit Care Med 2007; 176(2)111–112
   PubMed Web of Science ®Google Scholar